Growth Metrics

Jazz Pharmaceuticals (JAZZ) Net Cash Flow (2016 - 2025)

Jazz Pharmaceuticals has reported Net Cash Flow over the past 16 years, most recently at $65.8 million for Q4 2025.

  • Quarterly Net Cash Flow fell 66.6% to $65.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.0 billion through Dec 2025, down 213.13% year-over-year, with the annual reading at -$1.0 billion for FY2025, 213.13% down from the prior year.
  • Net Cash Flow was $65.8 million for Q4 2025 at Jazz Pharmaceuticals, down from $136.0 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $1.0 billion in Q1 2021 and troughed at -$1.2 billion in Q2 2021.
  • The 5-year median for Net Cash Flow is $60.1 million (2023), against an average of $16.9 million.
  • Peak annual rise in Net Cash Flow hit 1495.57% in 2021, while the deepest fall reached 1538.39% in 2021.
  • Tracing JAZZ's Net Cash Flow over 5 years: stood at -$78.9 million in 2021, then soared by 147.11% to $37.2 million in 2022, then soared by 353.98% to $168.8 million in 2023, then grew by 16.7% to $197.0 million in 2024, then crashed by 66.6% to $65.8 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $65.8 million, $136.0 million, and -$676.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.